79 related articles for article (PubMed ID: 608542)
1. Further studies on the serological effects of C. parvum immunotherapy in cancer patients.
James K; Merriman J; Woodruff MF; McCormick JN; McBride WH; Innes J; Horne NW
Dev Biol Stand; 1977 Apr 13-15; 38():501-6. PubMed ID: 608542
[TBL] [Abstract][Full Text] [Related]
2. Corynebacterium parvum: antibodies measured with the enzyme-linked immunosorbent assay (ELISA) in normal human sera and sera from cancer patients undergoing treatment.
Ruitenberg EJ; Buys J; Ursem PS
Ann Immunol (Paris); 1982; 133D(3):305-11. PubMed ID: 7165281
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
Drapkin R; Bjornsson S; Naeher C; Higby D; Caracandas J; Wallens WT; Kuberka N; Suh K; Siddiqi N; Henderson ES
Cancer Treat Rep; 1980; 64(12):1367-9. PubMed ID: 7193520
[TBL] [Abstract][Full Text] [Related]
4. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
6. Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.
Thatcher N; Honeybourne D; Wagstaff J; Carroll KB; Barber PV; Morrison JB; Crowther D
Br J Dis Chest; 1984 Jan; 78(1):89-97. PubMed ID: 6318791
[TBL] [Abstract][Full Text] [Related]
7. [Immunopotentiation in the treatment of malignant diseases. Cellular immunity in patients with malignoma of the lung treated with Corynebacterium parvum].
Dujić A; Dangubić V; Lilić D; Kolasinović N
Vojnosanit Pregl; 1982; 39(4):298-301. PubMed ID: 7147792
[No Abstract] [Full Text] [Related]
8. Antibody responses, antitumour antibodies and Ig class and subclass levels in C. parvum treated mice.
James K
Dev Biol Stand; 1977 Apr 13-15; 38():173-81. PubMed ID: 608503
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
Mitcheson HD; Priestman TJ
Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
[No Abstract] [Full Text] [Related]
10. [Stimulating immunity with the use of Corynebacterium parvum after resection of carcinoma of bronchial origin. Clinical aspects].
Dangubić V; Dujić A; Lilić D; Kolasinović N; Jeremić K
Srp Arh Celok Lek; 1982 Sep; 110(9):1017-24. PubMed ID: 7182936
[No Abstract] [Full Text] [Related]
11. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
[TBL] [Abstract][Full Text] [Related]
12. Non-specific immunostimulation in bronchogenic cancer.
Israel L
Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
[No Abstract] [Full Text] [Related]
13. Immunochemotherapy with Corynebacterium parvum in disseminated cancer.
Israel L
Ann N Y Acad Sci; 1976; 277(00):241-51. PubMed ID: 187100
[No Abstract] [Full Text] [Related]
14. Immunological response in patients receiving Corynebacterium parvum therapy.
Osborn DE; Castro JE
Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
[No Abstract] [Full Text] [Related]
15. Clinical studies with Corynebacterium parvum.
Mitcheson HD; Castro JE
Dev Biol Stand; 1977 Apr 13-15; 38():509-14. PubMed ID: 344105
[TBL] [Abstract][Full Text] [Related]
16. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.
James K; Clunie GJ; Woodruff MF; McBride WH; Stimson WH; Drew R; Catty D
Br J Cancer; 1975 Sep; 32(3):310-22. PubMed ID: 61040
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
20. [Immunologic disorders in lung malignancies and possibilities of immuno-corrective therapy].
Vucković Lj; Stanojević N; Rajner L; Susnjar S
Glas Srp Akad Nauka Med; 1991; (41):87-96. PubMed ID: 1916451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
